Protalix Biotherapeutics

Yahoo Finance • 24 days ago

PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the Com... Full story

Yahoo Finance • last month

Vantage Drilling International Ltd. – Announcement of Contract Termination

Dubai, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Vantage Drilling International Ltd. (the "Company”) announces the immediate termination of the contract for the Platinum Explorer for its approximately 260-day campaign. The termination is due to... Full story

Yahoo Finance • last month

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

PARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Prot... Full story

Yahoo Finance • 2 months ago

MPLX LP (MPLX) Price Target Cut Slightly, Rating Stays ‘Overweight’

MPLX LP (NYSE:MPLX) is among the most profitable oil stocks to buy now. Analysts at Wells Fargo have reiterated their ‘Overweight’ rating on MPLX LP (NYSE:MPLX), while cutting the price target to $59.00 from $60.00, implying a potential su... Full story

Yahoo Finance • 2 months ago

3 Penny Stocks With Market Caps Over $30M To Consider

As the Nasdaq and S&P 500 reach record highs, investors are keenly watching the Federal Reserve's upcoming interest rate decision, which could influence market dynamics. Penny stocks may be a throwback term, but the opportunities they repr... Full story

Yahoo Finance • 3 months ago

Vantage Drilling International Ltd. – Further Extension of Conditional Letter of Award

Dubai, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Vantage Drilling International Ltd. (the "Company") announces that the Conditional Letter of Award received for the Platinum Explorer dated 23 April 2025, as extended for 30 days on 22 July 2025,... Full story

Yahoo Finance • 4 months ago

Protalix BioTherapeutics appoints Gilad Mamlok as CFO

* Protalix BioTherapeutics (NYSE:PLX [https://seekingalpha.com/symbol/PLX]) Monday announced [https://seekingalpha.com/pr/20171526-protalix-biotherapeutics-appoints-gilad-mamlok-as-its-new-senior-vice-president-and-chief]the appointment... Full story

Yahoo Finance • 5 months ago

Earnings call transcript: Pluxee NV Q3 2025 sees stock rise despite revenue miss

Pluxee NV’s Q3 2025 earnings call revealed a revenue of €310 million, falling short of the €319 million forecast. Despite this, the company’s stock surged 7.78%, closing at €20.64, driven by strong organic growth and strategic initiatives.... Full story

Yahoo Finance • 5 months ago

Pluxee Q3 Fiscal 2025 slides: Double-digit revenue growth continues, objectives reaffirmed

Pluxee NV (EURONEXT:PLX) reported continued strong performance in its Q3 Fiscal 2025 results presentation on July 3, 2025, with double-digit organic revenue growth and reaffirmed financial objectives for the full year. The employee benefit... Full story

Yahoo Finance • 5 months ago

Pluxee posts 11.1% organic revenue growth in Q3 on solid volumes

Investing.com -- Pluxee (EPA:PLX) on Thursday posted total revenues of €310 million in the third quarter of fiscal 2025, up 11.1% organically from a year earlier. Reported revenue growth was 4.3%, influenced by a 10.3% adverse currency eff... Full story

Yahoo Finance • 2 years ago

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology compan... Full story

Yahoo Finance • 3 years ago

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

Milestone payment triggered by FDA approval of ELFABRIO® (pegunigalsidase alfa-iwxj) and payable within 30 days of approval CARMIEL, Israel, May 18, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceut... Full story

Yahoo Finance • 3 years ago

Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 4, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and co... Full story

Yahoo Finance • 3 years ago

Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

PRX-115 is a PEGylated recombinant uricase produced from the proprietary ProCellEx® platform as a potential treatment of severe gout CARMIEL, Israel, March 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE... Full story

Yahoo Finance • 3 years ago

Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production... Full story

Yahoo Finance • 4 years ago

Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 31, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, producti... Full story